Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry.
to study the efficacy and safety of indigenously developed tenecteplase injection in the management of Indian STEMI patients in clinical practice. post-licensure, observational, prescription event monitoring study. 2100 patients received weight-adjusted tenecteplase injection. More than 90% patients received aspirin, clopidogrel, and enoxaparin/heparin. Clinically successful thrombolysis was reported in 86.71%, in-hospital mortality was 3.48%. The adverse events recorded were comparable with previously published data. Any bleeding (excluding intra-cranial hemorrhage) was seen in 4.62% patients which was reported in 0.90% patients of which 47.34% patients had also received GpIIb/IIIa inhibitors. This study confirms the efficacy and safety of indigenous tenecteplase in Indian STEMI patients.